Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
Eli Lilly’s weight loss pill Foundayo has had a “slower-than-hoped” launch, according to BMO Capital Markets, which contended that the indirect comparison data—despite falling short of definitive proof of superiority—could help the Indiana giant build momentum for its oral drug.
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses Read More »
